Revolution Medicines CFO discloses 3,104-share Rule 10b5-1 sale

Revolution Medicines, Inc. Chief Financial Officer reports a planned share sale.

Accepted by SEC EDGAR 12/18/2025 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Financial Officer reports a planned share sale. CFO Jack Anders disclosed the sale of 3,104 shares of common stock on 12/16/2025 at a price of $77.0904 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy his tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.

Following this transaction, Anders beneficially owns 108,065 shares of Revolution Medicines common stock. This figure includes 175 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025 and 42,338 restricted stock units, which represent a right to receive shares in the future subject to vesting conditions.

Insider Trade Summary

Net Seller: 3,104 shares

Net Sell 1 txn

Insider Anders Jack

Role Chief Financial Officer

Sold 3,104 shs ($239K)

Share of Position Sold 2.8%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,104	$77.0904	$239K

Holdings After Transaction: Common Stock — 108,065 shares (Direct)

Holdings Before and After: Common Stock, 111,169 to 108,065 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. Includes 175 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2025.
3. F3. Includes 42,338 restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Revolution Medicines (RVMD) disclose?

Revolution Medicines disclosed that its Chief Financial Officer, Jack Anders, sold 3,104 shares of common stock on 12/16/2025 at $77.0904 per share.

Was the RVMD CFO stock sale made under a Rule 10b5-1 plan?

Yes. The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to address tax withholding on RSU vesting after July 15, 2023.

How many Revolution Medicines shares does the CFO own after the transaction?

After the reported sale, CFO Jack Anders beneficially owns 108,065 shares of Revolution Medicines common stock.

Does the CFOs reported ownership in RVMD include restricted stock units?

Yes. The reported total beneficial ownership of 108,065 shares includes 42,338 restricted stock units (RSUs), which may convert into shares upon vesting.

What role did tax withholding play in the RVMD CFOs share sale?

The filing states the sale was made to satisfy tax withholding obligations arising from the vesting of RSUs after July 15, 2023 under the 10b5-1 instruction letter.

What shares did the RVMD CFO acquire through the Employee Stock Purchase Plan?

The filing notes that the CFOs holdings include 175 shares acquired on November 30, 2025 under Revolution Medicines Employee Stock Purchase Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		S(1)		3,104	D	$77.0904	108,065(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 175 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2025.

3. Includes 42,338 restricted stock units.

	/s/ Jack Anders	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.